Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

OSTEOARTHRITIS

Disease modification in OA — will we ever get there?

Nature Reviews Rheumatology volume 15, pages 133–135 (2019)Cite this article

Subjects

No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Challenges for DMOAD trial design.

References

  1. McAlindon, T. E. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22, 363–388 (2014).

    Article  CAS  Google Scholar 

  2. Kraus, V. B. et al. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA’s accelerated approval regulations for disease modifying osteoarthritis drugs. Osteoarthritis Cartilage https://doi.org/10.1016/j.joca.2018.11.002 (2018).

    Article  PubMed  Google Scholar 

  3. National Joint Registry. Joint replacement statistics. njrcentre http://www.njrcentre.org.uk/njrcentre/Patients/Joint-replacement-statistics (2017).

  4. Hunter, D. J. Pharmacologic therapy for osteoarthritis —the era of disease modification. Nat. Rev. Rheumatol. 7, 13–22 (2011).

    Article  CAS  Google Scholar 

  5. Deveza, L. A. et al. Trajectories of femorotibial cartilage thickness among persons with or at risk of knee osteoarthritis: development of a prediction model to identify progressors. Osteoarthritis Cartilage 27, 257–265 (2019).

    Article  PubMed  Google Scholar 

  6. Neogi, T. et al. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ 339, b2844 (2009).

    Article  Google Scholar 

  7. Neogi, T. & Felson, D. T. Bone as an imaging biomarker and treatment target in OA. Nat. Rev. Rheumatol. 12, 503–504 (2016).

    Article  CAS  Google Scholar 

  8. Gossec, L. et al. The role of pain and functional impairment in the decision to perform total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. Osteoarthritis Cartilage 19, 147–154 (2011).

    Article  CAS  Google Scholar 

  9. Tubach, F. et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann. Rheum. Dis. 64, 34–37 (2005).

    Article  CAS  Google Scholar 

  10. Ingelsrud, L. H. et al. Meaningful change scores in the knee injury and osteoarthritis outcome score in patients undergoing anterior cruciate ligament reconstruction. Am. J. Sports Med. 46, 1120–1128 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Sciences Lund, Orthopaedics, Faculty of Medicine, Lund University, Lund, Sweden

    L. Stefan Lohmander

  2. Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark

    Ewa M. Roos

Authors
  1. L. Stefan Lohmander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ewa M. Roos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Stefan Lohmander.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lohmander, L.S., Roos, E.M. Disease modification in OA — will we ever get there?. Nat Rev Rheumatol 15, 133–135 (2019). https://doi.org/10.1038/s41584-019-0174-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-019-0174-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing